Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients

Abstract Purpose Our purpose was to evaluate the influence of obesity on clinicopathological characteristics of breast cancer. Secondly we wanted to explore the effect of obesity on the performance of endocrine therapy in Chinese breast cancer patients. Methods Patients with luminal/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer were included and categorized into the non-obese (BMI < 28 kg/m²) and obese (BMI ≥ 28 kg/m²) groups according to body mass index (BMI). Clinicopathological characteristics and treatment modalities were compared among two groups. Furthermore, the interaction of adjuvant endocrine therapy and efficacy between non-obese and obese groups were analyzed. Results A total of 2875 patients were included: 2598 in the non-obese group and 277 in the obese group. A higher rate of patients with comorbidities (OR: 2.83, 95%CI 2.13–3.74, P < 0.001) or PR positive tumor (OR: 1.63, 95%CI 1.03–2.58, P = 0.037) were identified in the obese group. Obesity was not associated with disease recurrence (P = 0.839) or overall survival (P = 0.140) in the whole population. Subgroup analysis did show an association with worse relapse-free survival (RFS, HR 3.48, 95%CI 1.31–9.22, P = 0.012) and overall survival (OS, HR 4.67, 95%CI 1.28–16.95, P = 0.019) in luminal A breast cancer. These results could not be reproduced in the luminal B subtype with a RFS (HR 0.78, 95%CI 0.41–1.49, P = 0.454) or OS (HR 1.17, 95%CI 0.50–2.74, P = 0.727). Furthermore, obesity didn’t impact endocrine therapy effectiveness, neither in Tamoxifen nor aromatase inhibitor group (RFS: interact P = 0.381; OS: interact P = 0.888). Conclusion The impact of obesity on prognosis interacted with luminal subtype status in Chinese breast cancer patients, which was not related with endocrine treatment modality.

Download Full-text

0057 The impact of the ratio of positive nodes to removed nodes on recurrence and overall survival in node positive breast cancer patients

The Breast ◽

10.1016/s0960-9776(09)70102-x ◽

2009 ◽

Vol 18 ◽

pp. S32

Author(s):

S. Lee ◽

J. Choi ◽

H. Lim ◽

W. Kim ◽

S. Kim ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Node Positive ◽

The Impact ◽

Positive Breast Cancer

Download Full-text

Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients

International Journal of Molecular Sciences ◽

10.3390/ijms222413540 ◽

2021 ◽

Vol 22 (24) ◽

pp. 13540

Author(s):

Judith Buentzel ◽

Henry Gerd Klemp ◽

Ralph Kraetzner ◽

Matthias Schulz ◽

Gry Helene Dihazi ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Molecular Subtype ◽

Ether Lipid ◽

Breast Cancer Patients ◽

Luminal A ◽

Luminal B ◽

High Concentrations ◽

A Minor

Malignant cells differ from benign ones in their metabolome and it is largely unknown whether this difference is reflected in the metabolic profile of their microvesicles (MV), which are secreted into the blood of cancer patients. Here, they are present together with MV from the various blood and endothelial cells. Harvesting MV from 78 breast cancer patients (BC) and 30 controls, we characterized the whole blood MV metabolome using targeted and untargeted mass spectrometry. Especially (lyso)-phosphatidylcholines and sphingomyelins were detected in a relevant abundance. Eight metabolites showed a significant discriminatory power between BC and controls. High concentrations of lysoPCaC26:0 and PCaaC38:5 were associated with shorter overall survival. Comparing BC subtype-specific metabolome profiles, 24 metabolites were differentially expressed between luminal A and luminal B. Pathway analysis revealed alterations in the glycerophospholipid metabolism for the whole cancer cohort and in the ether lipid metabolism for the molecular subtype luminal B. Although this mixture of blood-derived MV contains only a minor number of tumor MV, a combination of metabolites was identified that distinguished between BC and controls as well as between molecular subtypes, and was predictive for overall survival. This suggests that these metabolites represent promising biomarkers and, moreover, that they may be functionally relevant for tumor progression.

Download Full-text

Occurrence of BRCA1–2 mutations and overall survival among breast cancer patients from Sardinia

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e22215 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e22215-e22215

Author(s):

G. Palmieri ◽

G. Palomba ◽

A. Loi ◽

A. Uras ◽

M. Budroni ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Geographical Distribution ◽

Germline Mutations ◽

Disease Stage ◽

Breast Cancer Patients ◽

Sardinian Population ◽

Incident Cases ◽

The Impact

e22215 Background: Germline mutations in BRCA1-2 genes have been demonstrated to increase the risk of developing breast cancer. Conversely, the impact of BRCA1–2 mutations on prognosis and survival of breast cancer patients is still debated. In this study, we extensively investigated the prevalence and geographical distribution of BRCA1–2 mutations in the entire genetically-homogeneous Sardinian population as well as tried to clarify the influence of such mutations on breast cancer-specific survival. Methods: Among incident cases during the period 1997–2002, a total of 512 breast cancer patients gave their consent to undergo BRCA1–2 mutation screening by DHPLC analysis and automated DNA sequencing. The Hakulinen, Kaplan- Meier, and Cox regression methods were used for both relative survival assessment and statistical analysis. Results: A lower breast cancer-specific overall survival rate was observed in BRCA1–2 mutation-positive patients after the first two years from diagnosis. However, survival rates were similar in both groups after five years from diagnosis. No significant difference was found for age of onset, disease stage, and primary tumour histopathology between the two subsets. The geographical distribution of BRCA1–2 mutations was related to specific three large areas of Sardinia: a) the northern area, linguistically different from the rest of the island (where a BRCA2–8765delAG mutation with founder effect was predominant); b) the central-eastern area, land of the ancient Sardinian population (where BRCA2 mutations are still largely more common thanBRCA1 mutations); and c) the south-western area, with many Phoenician and Carthaginian locations (where BRCA1 mutations are prevalent). Conclusions: In Sardinian breast cancer population, the effects of BRCA1–2 germline mutations on patients' survival were demonstrated to vary within the first two years from diagnosis. After a longer follow-up observation, breast cancer-specific rates of death were instead similar for BRCA1–2 mutation carriers and non-carriers. Finally, we identified some probands' phenotypic features which may be predictive for the presence of BRCA1–2 germline mutations and should be therefore considered when counselling patients about undergoing genetic testing. No significant financial relationships to disclose.

Download Full-text

The prognostic role of androgen receptor in early-stage breast cancer patients: A meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.528 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 528-528 ◽

Cited By ~ 1

Author(s):

Ivana Bozovic-Spasojevic ◽

Dimitrios Zardavas ◽

Evandro De Azambuja ◽

Lieveke Ameye ◽

Christos Sotiriou ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Androgen Receptor ◽

Cancer Patients ◽

Early Stage ◽

Meta Analysis ◽

Prognostic Impact ◽

Breast Cancer Patients ◽

Prognostic Role ◽

The Impact

528 Background: Androgen receptor (AR) expression has been observed in ~70% of breast cancer (BC) patients, but its prognostic role is not established yet. To assess this we performed a meta-analysis of studies that evaluated the impact of AR on disease free survival (DFS) and/or on overall survival (OS) in early stage BC. Methods: Published studies were identified by an electronic search on PubMed using the MeSH terms "breast neoplasm" and "androgen receptor" (up to June 2012). Identified studies were assessed against the following criteria for inclusion in the analysis: early stage BC and reported results of AR status in correlation with clinical outcome. We report combined HRs with 95% confidence intervals (CI) using AR negative patients as reference. Results: Twenty studies were eligible for the meta-analysis out of 493 initially identified and 12 among them, including 6,525 patients, were considered as evaluable (i.e., reporting enough information to allow aggregation of results). AR positivity was associated with lower risk of relapse in all breast cancer patients, and better overall survival in both univariate (U) and multivariate (M) analysis. AR prognostic impact in different subtypes was also assessed (see Table). Conclusions: Our analysis demonstrated that AR delivers prognostic information overall, serving as a positive prognostic factor in early stage BC. Further studies are needed to delineate its prognostic impact within the different subtypes of the disease. [Table: see text]

Download Full-text